NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma raises $47M in series A investment round from INKEF and existing investors, to advance treatments of neuromuscular disorders | Nordic 9
Detailed Description | NMD-GPS
NMD Pharma - Capnova
PDF) A missense mutation in the putative sarcoplasmic reticulum transmembrane protein DCST2 causes dominant strongman syndrome
Investors — NMD Pharma
NMD Pharma
Company Presentation
NMD Pharma
NMD Pharma on Vimeo
Management — NMD Pharma
NMD Pharma, finalist i Life Sciences kategorien - EY Danmark
Company Presentation
NMD Pharma brænder 41 mio. kr. af sin kæmpeinvestering
NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma - Crunchbase Company Profile & Funding
Erhverv Aarhus - 照片| Facebook
NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma Information | NMD Pharma Profile
Nete Huus's email & phone | NMD Pharma ApS's Senior Scientist email
ALS Archives - Labiotech.eu
NMD Pharma — NMD Pharma
Denmark in New York on Twitter: "#DKBIO17 is "a great opportunity for us to broaden our scope and look for investors.” - Thomas H. Pedersen, CEO, NMD Pharma… https://t.co/AUeO5JqgX6"
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
Prominent Canadian researcher in Denmark: Why I left a top job in California
